Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 16/20 | 0.64 |
| ▸ | CDK4 | P11802 | 7/20 | 0.64 |
| ▸ | CCND2 | P30279 | 1/20 | 0.64 |
| ▸ | CCND3 | P30281 | 1/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 17/20 | 0.52 |
| ▸ | CDK2 | P24941 | 17/20 | 0.52 |
| ▸ | CDK6 | Q00534 | 15/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.50 |
| ▸ | CDK9 | P50750 | 6/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310099 | 0.90 | CCND1 (0.67) | CCND1CDK4CCND2CCND3CCNE1 | |
| SCHEMBL3300306 | 0.84 | CCND1 (0.71) | CCND1CDK4CCND2CCND3CCNE1 | |
| SCHEMBL3304050 | 0.83 | CCND1 (0.79) | CCND1CDK4CCND2CCND3CCNE1 | |
| SCHEMBL3301745 | 0.81 | CCND1 (0.72) | CCND1CDK4CCND2CCND3CCNE1 | |
| SCHEMBL3305407 | 0.81 | CCND1 (0.72) | CCND1CDK4CCND2CCND3CCNE1 | |
| SCHEMBL4359995 | 0.79 | CCND1 (1.00) | CCND1CDK4CCND2CCND3CCNE1 | |
| SCHEMBL3300919 | 0.78 | CCND1 (0.61) | CCND1CDK4CCND2CCND3CCNE1 | |
| SCHEMBL3304075 | 0.77 | CCND1 (0.66) | CCND1CDK4CCND2CCND3CCNE1 | |
| SCHEMBL7797717 | 0.77 | CCND1 (0.66) | CCND1CDK4CCND2CCND3CCNE1 | |
| SCHEMBL24670367 | 0.75 | CCND1 (0.72) | CCND1CDK4CCND2CCND3CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404695-B2 | Pyrimidinyl pyridone inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404695-B2 | Pyrimidinyl pyridone inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2010046273-A2 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-29 | — | — | WO | disclosed |
| US-20100099691-A1 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | ROCHE PALO ALTO LLC | 2010-04-22 | — | — | US | disclosed |
| US-20100099691-A1 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | ROCHE PALO ALTO LLC | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099691-A1 | PYRIMIDINYL PYRIDONE INHIBITORS OF JNK | MAP3K20, MAP3K6, MAP3K1 | CCND1 506/4885CDK4 168/4885CCND2 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.